1. Home
  2. PHVS vs PRLB Comparison

PHVS vs PRLB Comparison

Compare PHVS & PRLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • PRLB
  • Stock Information
  • Founded
  • PHVS 2015
  • PRLB 1999
  • Country
  • PHVS Switzerland
  • PRLB United States
  • Employees
  • PHVS N/A
  • PRLB N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • PRLB Metal Fabrications
  • Sector
  • PHVS Health Care
  • PRLB Industrials
  • Exchange
  • PHVS Nasdaq
  • PRLB Nasdaq
  • Market Cap
  • PHVS 980.9M
  • PRLB 928.0M
  • IPO Year
  • PHVS 2021
  • PRLB 2012
  • Fundamental
  • Price
  • PHVS $20.06
  • PRLB $46.83
  • Analyst Decision
  • PHVS Buy
  • PRLB Hold
  • Analyst Count
  • PHVS 6
  • PRLB 3
  • Target Price
  • PHVS $37.17
  • PRLB $43.50
  • AVG Volume (30 Days)
  • PHVS 216.0K
  • PRLB 192.3K
  • Earning Date
  • PHVS 08-13-2025
  • PRLB 07-31-2025
  • Dividend Yield
  • PHVS N/A
  • PRLB N/A
  • EPS Growth
  • PHVS N/A
  • PRLB N/A
  • EPS
  • PHVS N/A
  • PRLB 0.61
  • Revenue
  • PHVS N/A
  • PRLB $508,637,000.00
  • Revenue This Year
  • PHVS N/A
  • PRLB $4.18
  • Revenue Next Year
  • PHVS N/A
  • PRLB $4.61
  • P/E Ratio
  • PHVS N/A
  • PRLB $76.11
  • Revenue Growth
  • PHVS N/A
  • PRLB N/A
  • 52 Week Low
  • PHVS $11.51
  • PRLB $26.35
  • 52 Week High
  • PHVS $26.33
  • PRLB $46.73
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 48.84
  • PRLB 76.61
  • Support Level
  • PHVS $20.06
  • PRLB $42.84
  • Resistance Level
  • PHVS $22.30
  • PRLB $44.60
  • Average True Range (ATR)
  • PHVS 1.13
  • PRLB 1.24
  • MACD
  • PHVS -0.23
  • PRLB 0.68
  • Stochastic Oscillator
  • PHVS 22.84
  • PRLB 89.44

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About PRLB Proto Labs Inc. Common stock

Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.

Share on Social Networks: